Rebamipide is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. Additionally, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Its therapeutic use is listed as gastrointestinal agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Proamipide, Mucosta, Rebator and Pramipide. Its PubChem CID is 5042.
Rebamipide
| CAS No | 90098-04-7 |
|---|---|
| Molecular Formula | C19H15ClN2O4 |
| Molecular Weight | 370.8 g/mol |
| Synonyms | 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rebamipide is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa.
The listed CAS number is 90098-04-7.
The listed molecular formula is C19H15ClN2O4.
The listed molecular weight is 370.8 g/mol.
2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid.
The source lists Proamipide, Mucosta, Rebator and Pramipide.